Glud EN, Rasmussen M, Zhang Y, Mandrup OA, et al. Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 x anti-PSMA bispecific design. Br J Cancer 2022 Oct 15. pii: 10.1038/s41416-022-01994.
PMID: 36243890